Inhibikase Therapeutics Inc (FRA:IQT0)
€ 3.21 0 (0%) Market Cap: 5.05 Mil Enterprise Value: -14.25 Mil PE Ratio: 0 PB Ratio: 4.07 GF Score: 40/100

Q1 2022 Inhibikase Therapeutics Inc Earnings Call Transcript

May 17, 2022 / 12:00PM GMT
Release Date Price: €3.84 (-5.19%)
Operator

Greetings. Welcome to Inhibikase Therapeutics' first-quarter 2022 financial results conference call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. (Operator Instructions)

Please note this conference is being recorded.

I will now turn the conference over to Alex Lobo, Stern Investor Relations. Thank you. You may begin.

Alex Lobo
Stern IR - IR

Thank you, Sherry. Good morning and welcome to Inhibikase Therapeutics' first-quarter 2022 financial results conference call and audio webcast.

With me today is Dr. Milton Werner, Chief Executive Officer; and Joseph Frattaroli, Chief Financial Officer.

Yesterday, Inhibikase issued a press release announcing financial results for the first quarter ended March 31, 2022. We encourage everyone to read yesterday's press release, as well as Inhibikase's quarterly report on Form 10-Q for the first-quarter 2022, which is being filed with the SEC. The company's press release and quarterly report are also available on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot